During Tuesday’s Afternoon trade, Shares of LKQ Corporation (NASDAQ:LKQ), lost -0.49% to $31.27.
LKQ Corporation (LKQ) has again been named to the Fortune 500 list, Fortune magazine’s annual ranking of America’s largest companies by revenue. LKQ had 2014 total revenue of $6.7 billion. Fortune magazine ranked LKQ No. 403 on its list contrast to No. 490 last year.
LKQ Corporation, together with its auxiliaries, distributes replacement parts, components, and systems used in the repair and maintenance of vehicles in the United States, the United Kingdom, the Netherlands, Belgium, Northern France, Canada, Mexico, and Central America. The company operates in four segments: Wholesale North America, Wholesale Europe, Self Service, and Specialty. It distributes various products, counting aftermarket collision and mechanical products; recycled collision and mechanical products; and refurbished collision replacement products, such as wheels, bumper covers and lights, and remanufactured engines.
Shares of Oncothyreon Inc (USA) (NASDAQ:ONTY), declined -5.30% to $3.12, during its Afternoon trading session.
Oncothyreon Inc. (ONTY) declared the presentation of positive data from the company’s ongoing trials of ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor for the treatment of breast cancer, at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting. The first presentation updated data from the Phase 1b trial of ONT-380 in combination with Xeloda(R) (capecitabine)and Herceptin(R) (trastuzumab) in third line treatment of HER2-positive metastatic breast cancer. The data support Oncothyreon’s plans to initiate a blinded, randomized, placebo-controlled Phase 2 trial in this indication. The second presentation focused on the role of ONT-380 in the treatment of HER2-positive breast cancer central nervous system (CNS) metastases.
Patients comprised of in the presentation on the role of ONT-380 in the treatment of CNS metastases were selected from the above trial and from an ongoing Phase 1b trial (ClinicalTrials.gov Identifier NCT01983501) of ONT-380 in combination with Kadcyla in patients who have been formerly treated with Herceptin and a taxane for metastatic breast cancer. Patients were comprised of if their presenting CNS lesions were evaluable for response using RECIST 1.1 criteria and they had either untreated, asymptomatic lesions having never received radiotherapy or surgery to the CNS (n=8) or new or progressive lesions following prior CNS therapy (n=14). Best CNS response was a CR in one patient, a PR in four patients and SD in nine patients. No patient had progressive disease as a CNS best response. One patient was not evaluable for response having undergone surgery for a symptomatic CNS lesion; pathologic examination of the resected specimen found no evidence of viable tumor. Two patients were not evaluated because of progressive disease outside of the CNS, while five patients in the series remain too early to evaluate.
Oncothyreon Inc., a clinical-stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of cancer. Its clinical-stage product candidates comprise ONT-380, an orally active and selective small-molecule HER2 inhibitor, which is in two Phase 1b trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin; and ONT-10, a therapeutic vaccine in Phase 1 trial targeting the Mucin 1 peptide antigen (MUC1) for use in various cancer indications, counting breast, thyroid, colon, stomach, pancreas, ovarian, and prostate, in addition to certain types of lung cancer.
Mast Therapeutics Inc (NYSEMKT:MSTX), during its Tuesday’s Afternoon trading session decreased -0.02% to $0.470.
Mast Therapeutics, Inc. (MSTX), a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, arterial disease and heart failure, stated financial results for the quarter ended June 30, 2015.
Second Quarter 2015 Operating Results
The Company’s net loss for the second quarter of 2015 was $10.2 million, or $0.06 per share (basic and diluted), contrast to a net loss of $7.2 million, or $0.06 per share (basic and diluted), for the same period in 2014.
Research and development (R&D) expenses for the second quarter of 2015 were $7.7 million, an enhance of $2.9 million, or 61%, contrast to $4.8 million for the same period in 2014. The enhance was due primarily to enhances of $1.9 million in external nonclinical study fees and expenses, $0.8 million in external clinical study fees and expenses and $0.2 million in personnel expenses.
The $1.9 million enhance in external nonclinical study fees and expenses was due primarily to a $1.7 million enhance in research-related manufacturing costs for vepoloxamer and a $0.2 million enhance in research-related manufacturing costs for AIR001. The $0.8 million enhance in external clinical study fees and expenses was due primarily to an enhance of $1.2 million in EPIC study costs, offset by a decrease of $0.4 million in AIR001 study costs.
Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for serious or life-threatening diseases. The company’s lead product candidate is MST-188 (vepoloxamer), an injection used for the treatment of sickle cell disease, arterial disease, and heart failure. It also develops AIR001, a sodium nitrite solution for intermittent inhalation via nebulizer, for the treatment of heart failure with preserved ejection fraction. The company was formerly known as ADVENTRX Pharmaceuticals, Inc. and changed its name to Mast Therapeutics, Inc. in March 2013. Mast Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Finally, OGE Energy Corp. (NYSE:OGE), decreased -1.27%, to $31.05.
The ASA/USA Softball Hall of Fame Museum and four-field complex has become the first softball venue and predominately women’s athletic venue in the country to earn the EPA Green Power Partnership with their commitment to offset 100 percent of its electricity consumption with renewable wind power, following a recent agreement with OGE Energy Corp. (OGE).
The 10-year agreement between ASA/USA Softball and OG&E provides the ASA Hall of Fame complex with renewable energy credits for its OGE Energy Field, ancillary fields, museum and administrative offices. This encompasses the new improvements with the completion of the first phase of its multi-million dollar renovation.
ASA/USA Softball and OG&E have partnered to create a state-of-the-art electric technology venue, an outcome of the 20-year agreement formed last year between OGE Energy Corp. and Oklahoma City All Sports Association to support the venue improvements required to retain the NCAA WCWS. Other elements of the partnership comprise the stadium field name, now called OGE Energy Field, in addition to adding a platform to educate fans and OG&E customers on wise energy use for residential and commercial application.
A partner of OGE Energy Corp., OG&E serves more than 800,000 customers in a service territory spanning 30,000 square miles in Oklahoma and Western Arkansas. The company is a leading provider of renewable energy in Oklahoma, accounting for 850 MW of renewable energy, representing about 10 percent of the company’s total generation capability.
OGE Energy Corp., together with its auxiliaries, operates as an energy and energy services provider that offers physical delivery and related services for electricity and natural gas primarily in the south central United States. The company operates in two segments, Electric Utility and Natural Gas Midstream Operations. The Electric Utility segment generates, transmits, distributes, and sells electric energy in Oklahoma and western Arkansas.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.